Key result
Approximately one-third of patients supported with left ventricular assist devices experience significant ventricular arrhythmias, which are associated with increased mortality and morbidity.
Why the study?
How should ventricular arrhythmias be managed in patients with long-term ventricular assist devices?
How should ventricular arrhythmias be managed in patients with long-term ventricular assist devices?
Ventricular arrhythmias are common in VAD-supported patients and are associated with increased mortality and morbidity, with current evidence supporting the use of ICDs and targeted ablation or mechanical adjustments.
Answers are grounded in this paper and cite their sources.
VA in one-third of LVAD patients link to higher mortality; extends observational associations but leaves optimal management unresolved.
PURPOSE OF REVIEW: To summarize the available evidence concerning the occurrence and treatment of ventricular arrhythmias in patients supported with long-term ventricular assist devices (VADs). RECENT FINDINGS: Approximately one-third of left ventricular assist device-supported patients experience significant ventricular arrhythmias, with higher rates in certain patient subsets. Ventricular arrhythmias are associated with both increased mortality and morbidity in VAD-supported patients. Mechanical factors, myocardial fibrosis and alterations in cardiac myocyte physiology because of myocardial unloading are contributors to ventricular arrhythmias in this population. In the absence of definitive trials, current evidence supports implanted cardioverter defibrillators (ICDs) in long-term VAD patients to mitigate the risks associated with ventricular arrhythmias. Though antiarrhythmic therapies have limited efficacy, amelioration of inflow cannula contact with the endocardium and suction events or ablation of specific anatomic origins of ventricular arrhythmias, when present, are also efficacious in VAD-supported hearts. SUMMARY: As the application of long-term VAD support continues to grow, it will be increasingly important to clarify and target the mechanisms contributing to ventricular arrhythmias in this population. Prospective trials assessing the benefits of de-novo ICD placement, ablative strategies and other prophylactic and therapeutic interventions will be increasingly important to further improve the survival and quality of life among VAD-supported patients.
No takes yet. Share an insight, caveat, or question.
Pedrotty et al. (2013) conducted a review in Ventricular arrhythmias in patients with ventricular assist devices. Management of ventricular arrhythmias (ICDs, antiarrhythmic therapies, ablation) was evaluated. Approximately one-third of patients supported with left ventricular assist devices experience significant ventricular arrhythmias, which are associated with increased mortality and morbidity.
Synapse has enriched 10 related papers. Consider them for comparative context: